

FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.  
NUTRI.018RAAPPLICATION NO.  
09/912,472INFORMATION DISCLOSURE STATEMENT  
BY APPLICANTAPPLICANT  
Mark F. McCartyFILING DATE  
July 24, 2001GROUP  
1614

(USE SEVERAL SHEETS IF NECESSARY)

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE (IF APPROPRIATE)
h	5,336,672	08/09/94	Southern, Jr. et al.			
h	5,470,846	11/29/95	Sandyk			
h	5,496,827	03/05/96	Patrick			
h	5,597,585	01/28/97	Williams et al.			
h	5,635,535	06/03/97	Wagstaff			

RECEIVED  
DEC 19 2002  
TECH CENTER 1600/2900

## FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
h	WO 91/11117	08/08/91	PCT WO				
h	WO 96/25939	08/29/96	PCT WO				

EXAMINER  
INITIAL

## OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)

h	Anderson, R.A. (1997) Nutritional factors influencing the glucose/insulin system: Chromium. Journal of the American College of Nutrition. 16(5):404-410.
h	Cefalu et al. (1997) The effect of chromium supplementation on carbohydrate metabolism and body fat distribution. Diabetes. 46:55a.
h	Maebashi et al. (1993) Therapeutic evaluation of the effect of biotin on hyperglycemia in patients with non-insulin dependent diabetes mellitus. J. Clin. Biochem. Nutr. 14:211-218.
h	McCarty (1991) The case for supplemental chromium and a survey of clinical studies with chromium picolinate. Journal of Applied Nutrition. 43(1):58-66.
h	Ravina et al. (1995) Clinical use of the trace element chromium (III) in the treatment of diabetes mellitus. The Journal of Trace Elements in Experimental Medicine. 8:183-190.

S:\DOCS\MKD\MKD-3356.DOC\120902

EXAMINER

DATE CONSIDERED

\*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.